Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial)

Ian T Meredith; Paul S Teirstein; Alain Bouchard; Didier Carrie; Helge Mollmann; Keith G Oldroyd; Jack Hall; Dominic J Allocco; Keith D Dawkins; Gregg W Stone

doi:10.1016/j.amjcard.2013.12.011

Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial)

Ian T Meredith, Paul S Teirstein, Alain Bouchard, Didier Carrie, Helge Mollmann, Keith G Oldroyd, Jack Hall, Dominic J Allocco, Keith D Dawkins, Gregg W Stone

Research output: Contribution to journal › Article › Research › peer-review

31 Citations (Scopus)

Abstract

Everolimus-eluting stents have become the most commonly used drug-eluting stents (DES), in part because of data from clinical trials showing significantly reduced rates of revasculization, myocardial infarction (MI), and stent thrombosis with the PROMUS or XIENCE V everolimus-eluting, cobalt-chromium stent compared with early generation paclitaxel-eluting stents.

Original language	English
Pages (from-to)	1117-1123
Number of pages	7
Journal	The American Journal of Cardiology
Volume	113
Issue number	7
DOIs	https://doi.org/10.1016/j.amjcard.2013.12.011
Publication status	Published - 2014
Externally published	Yes

Access to Document

10.1016/j.amjcard.2013.12.011

Cite this

Meredith, I. T., Teirstein, P. S., Bouchard, A., Carrie, D., Mollmann, H., Oldroyd, K. G., Hall, J., Allocco, D. J., Dawkins, K. D., & Stone, G. W. (2014). Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial). The American Journal of Cardiology, 113(7), 1117-1123. https://doi.org/10.1016/j.amjcard.2013.12.011

@article{7a738cea5a874a13a51dddc594b610b0,

title = "Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial)",

abstract = "Everolimus-eluting stents have become the most commonly used drug-eluting stents (DES), in part because of data from clinical trials showing significantly reduced rates of revasculization, myocardial infarction (MI), and stent thrombosis with the PROMUS or XIENCE V everolimus-eluting, cobalt-chromium stent compared with early generation paclitaxel-eluting stents.",

author = "Meredith, {Ian T} and Teirstein, {Paul S} and Alain Bouchard and Didier Carrie and Helge Mollmann and Oldroyd, {Keith G} and Jack Hall and Allocco, {Dominic J} and Dawkins, {Keith D} and Stone, {Gregg W}",

year = "2014",

doi = "10.1016/j.amjcard.2013.12.011",

language = "English",

volume = "113",

pages = "1117--1123",

journal = "The American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier",

number = "7",

}

Meredith, IT, Teirstein, PS, Bouchard, A, Carrie, D, Mollmann, H, Oldroyd, KG, Hall, J, Allocco, DJ, Dawkins, KD & Stone, GW 2014, 'Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial)', The American Journal of Cardiology, vol. 113, no. 7, pp. 1117-1123. https://doi.org/10.1016/j.amjcard.2013.12.011

Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial). / Meredith, Ian T; Teirstein, Paul S; Bouchard, Alain et al.

In: The American Journal of Cardiology, Vol. 113, No. 7, 2014, p. 1117-1123.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial)

AU - Meredith, Ian T

AU - Teirstein, Paul S

AU - Bouchard, Alain

AU - Carrie, Didier

AU - Mollmann, Helge

AU - Oldroyd, Keith G

AU - Hall, Jack

AU - Allocco, Dominic J

AU - Dawkins, Keith D

AU - Stone, Gregg W

PY - 2014

Y1 - 2014

N2 - Everolimus-eluting stents have become the most commonly used drug-eluting stents (DES), in part because of data from clinical trials showing significantly reduced rates of revasculization, myocardial infarction (MI), and stent thrombosis with the PROMUS or XIENCE V everolimus-eluting, cobalt-chromium stent compared with early generation paclitaxel-eluting stents.

AB - Everolimus-eluting stents have become the most commonly used drug-eluting stents (DES), in part because of data from clinical trials showing significantly reduced rates of revasculization, myocardial infarction (MI), and stent thrombosis with the PROMUS or XIENCE V everolimus-eluting, cobalt-chromium stent compared with early generation paclitaxel-eluting stents.

UR - http://www.sciencedirect.com/science/article/pii/S000291491400037X

U2 - 10.1016/j.amjcard.2013.12.011

DO - 10.1016/j.amjcard.2013.12.011

M3 - Article

VL - 113

SP - 1117

EP - 1123

JO - The American Journal of Cardiology

JF - The American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -

Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial)

Abstract

Access to Document

Other files and links

Cite this